Legal & General Group Plc Boosts Stock Position in Applied Therapeutics, Inc. (NASDAQ:APLT)

Legal & General Group Plc boosted its holdings in shares of Applied Therapeutics, Inc. (NASDAQ:APLT) by 293.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 84,018 shares of the company’s stock after purchasing an additional 62,686 shares during the period. Legal & General Group Plc owned about 0.07% of Applied Therapeutics worth $72,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Private Advisor Group LLC bought a new stake in shares of Applied Therapeutics during the 4th quarter valued at about $35,000. SG Americas Securities LLC boosted its position in Applied Therapeutics by 169.0% during the 4th quarter. SG Americas Securities LLC now owns 40,747 shares of the company’s stock valued at $35,000 after acquiring an additional 25,601 shares in the last quarter. Intech Investment Management LLC grew its holdings in shares of Applied Therapeutics by 176.1% during the 4th quarter. Intech Investment Management LLC now owns 52,631 shares of the company’s stock worth $45,000 after acquiring an additional 33,567 shares during the period. Swiss National Bank bought a new position in shares of Applied Therapeutics in the 4th quarter worth approximately $126,000. Finally, Aristides Capital LLC purchased a new position in shares of Applied Therapeutics in the 4th quarter valued at approximately $134,000. Institutional investors own 98.31% of the company’s stock.

Applied Therapeutics Price Performance

Shares of Applied Therapeutics stock opened at $0.41 on Friday. Applied Therapeutics, Inc. has a 1 year low of $0.30 and a 1 year high of $10.62. The firm has a market cap of $58.70 million, a price-to-earnings ratio of -0.26 and a beta of 1.88. The company has a 50-day moving average of $0.45 and a 200 day moving average of $2.59.

Applied Therapeutics (NASDAQ:APLT) last posted its earnings results on Monday, April 14th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.06). The business had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.61 million. On average, equities analysts anticipate that Applied Therapeutics, Inc. will post -0.65 EPS for the current year.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.